spacer
home > epc > winter 2019 > realising international data access through data collaborations
PUBLICATIONS
European Pharmaceutical Contractor

Realising International Data Access through Data Collaborations

International clinical trials and the commercialisation of new precision medicines across global markets require access to real-world data (RWD). With access to RWD on a global scale, pharmaceutical companies are empowered to derive valuable insights that translate into more patients for clinical trials, faster time to market, and increased revenues in international markets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Randy Ramin-Wright is the Site & Patient Network Director at Clinerion. Randy holds a Bachelor of Science in astrophysics and a Master of Science in physics from the Michigan State University, US. He has more than 20 years’ experience in consulting, risk management, and information management systems implementation.

Le Vin Chin is Head of Marketing and Communications at Clinerion and has been working in communications and marketing for 20 years, in a wide variety of industries, including software and services.
spacer
Randy Ramin-Wright
spacer
spacer
spacer
Le Vin Chin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement